Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to a deferred bonus plan.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details specific increases in American Depositary Shares (ADSs) held by two individuals following the re-investment of dividends paid on October 3, 2013, at a price of $50.083 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports the mechanics of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan, noting that notional dividends accrued under the matching element will be paid out based on vesting percentages after the relevant measurement period.
Investor Verification Points
- Verify the total number of ADSs acquired by Mrs. D P Connelly (34.463 personal + 35.699 matching) and Mr. W C Louv (25.319 personal + 26.159 matching).
- Confirm the dividend reinvestment price of $50.083 per ADS.
- Note that these transactions relate to deferred bonuses from 2010, 2011, and 2012 on a post-tax basis.
- Understand that this filing does not contain financial performance data for the period.